Vesicular stomatitis virus (VSV) is being investigated as an oncolytic agent due to its capacity to kill cancer cells while exhibiting low virulence in vivo. A trigger for cancer metastasis is the formation of structures known as invadopodia, which function in extracellular matrix (ECM) degradation. I hypothesized that VSV alters invadopodia structures and inhibits their proteolytic function due to the ability of VSV to inhibit host gene expression. My results showed that, following infection with VSV, Src-transformed fibroblasts formed lowered numbers of invadopodia, but yielded increased numbers of ring shaped invadopodia superstructures called rosettes. Overall, there was a decreased ability of cells to degrade ECM and express the invado...
The ability of certain viruses to exploit cancer cell abnormalities for their own replication repres...
Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a ...
Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection; however...
Cancer is one of the most deadly diseases around the world. Oncolytic virus (OV) therapy is an anti-...
Vesicular stomatitis virus (VSV) is a promising oncolytic agent that directly kills cancer cells, bu...
The human immune system is dedicated to ridding the body of foreign pathogens. However, in the conte...
Vesicular Stomatitis Virus (VSV) is a good candidate for oncolytic therapy due to its ability to ind...
AbstractSelected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to...
AbstractIdeally, an oncolytic virus will replicate preferentially in malignant cells, have the abili...
Macrophages of the tumor microenvironment form cytoskeletal adhesion structures called podosomes tha...
Oncolytic virotherapy is an exciting field that is currently generating a significant amount of inte...
AbstractVesicular stomatitis virus (VSV) exerts potent antitumor activity, although the molecular me...
Cancer cells do not act autonomously. The interaction between cancer cells and other ‘normal’ cell t...
Oncolytic viruses (OVs) are selected or designed to eliminate malignancies by direct infection and l...
Vesicular stomatitis virus (VSV) has been widely used to characterize cellular processes, viral resi...
The ability of certain viruses to exploit cancer cell abnormalities for their own replication repres...
Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a ...
Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection; however...
Cancer is one of the most deadly diseases around the world. Oncolytic virus (OV) therapy is an anti-...
Vesicular stomatitis virus (VSV) is a promising oncolytic agent that directly kills cancer cells, bu...
The human immune system is dedicated to ridding the body of foreign pathogens. However, in the conte...
Vesicular Stomatitis Virus (VSV) is a good candidate for oncolytic therapy due to its ability to ind...
AbstractSelected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to...
AbstractIdeally, an oncolytic virus will replicate preferentially in malignant cells, have the abili...
Macrophages of the tumor microenvironment form cytoskeletal adhesion structures called podosomes tha...
Oncolytic virotherapy is an exciting field that is currently generating a significant amount of inte...
AbstractVesicular stomatitis virus (VSV) exerts potent antitumor activity, although the molecular me...
Cancer cells do not act autonomously. The interaction between cancer cells and other ‘normal’ cell t...
Oncolytic viruses (OVs) are selected or designed to eliminate malignancies by direct infection and l...
Vesicular stomatitis virus (VSV) has been widely used to characterize cellular processes, viral resi...
The ability of certain viruses to exploit cancer cell abnormalities for their own replication repres...
Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a ...
Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection; however...